Europe Inflammatory Bowel Disease Treatment Market By Type (Crohn's Disease and Ulcerative Colitis), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Online Pharmacy), By Route of Administration (Injectable and Oral), By Drug Class (TNF inhibitors, Anti-integrin, IL inhibitors, Corticosteroids, JAK inhibitors, Aminosalicylates and Others), By Country, Opportunity Analysis and Industry Forecast, 2021 - 2027
Special Offering: Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
Get in-depth analysis of the COVID-19 impact on the Europe Inflammatory Bowel Disease Treatment Market
Market Report Description
The Europe Inflammatory Bowel Disease Treatment Market would witness market growth of 7.3% CAGR during the forecast period (2021-2027).
The main types of inflammatory disease are ulcerative colitis and Crohn’s disease. Patients suffering from Crohn’s disease may experience swelling and pain in the digestive tract. Also, patients can witness its effect on any part of the body from the mouth to the anus. It has a greater impact on the upper part of the large intestine and whole small intestine, majorly. In ulcerative colitis, patients witness swelling and sores (ulcers) in the large intestine (colon and rectum). Moreover, it causes intestinal inflammation that can be identified using a microscope.
The stressful & sedentary lifestyle and growing consumption of unhealthy drinks & food, leads to different digestive disorders and hence, boosting the demand for the market. Additionally, government and private companies are heavily investing in the healthcare sector which is estimated to escalate the growth of the market. Moreover, increasing research and development activities related to inflammatory bowel disease drugs will create new growth avenues for the inflammatory bowel disease treatment market in the forthcoming years. On the other hand, harmful effects like nausea, cramps, loss of appetite, and mild stomach pain, strict government regulations coupled with the efficacy and safety of the drug, and higher cost of drugs are the factors that would slow down the growth of the market in the coming years.
The inflammatory bowel disease treatment market is strongly growing in Europe. Europe comprises various well-established nations such as Spain, Norway, Germany, Italy, the UK, and France that are contributing to the growth of the inflammatory bowel disease treatment market. The increasing number of individuals engaged in smoking, evolving lifestyle, and rising prevalence of inflammatory bowel disease treatment are the factors supporting the growth of the market in this region.
Besides, the European Federation of Crohn's & Ulcerative Colitis Associations is the organization that continuously monitors inflammatory bowel disease patients in the region and is highly involved in the development of alternatives for inflammatory bowel disease treatment. Moreover, unhealthy eating and smoking practice, especially among youngsters has led to an increase in the prevalence of inflammatory bowel disease. Thus, these factors are anticipated to boost the demand and growth of the regional inflammatory bowel disease treatment market in the forthcoming period.
The Germany market dominated the Europe Aminosalicylates Inflammatory Bowel Disease Treatment Market by Country 2020, thereby, achieving a market value of $169.8 million by 2027. The UK market is exhibiting a CAGR of 8.8% during (2021 - 2027). Additionally, The France market is anticipated to witness a CAGR of 11.2% during (2021 - 2027).
Based on Type, the market is segmented into Crohn's Disease and Ulcerative Colitis. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Online Pharmacy. Based on Route of Administration, the market is segmented into Injectable and Oral. BBased on Drug Class, the market is segmented into TNF inhibitors, Anti-integrin, IL inhibitors, Corticosteroids, JAK inhibitors, Aminosalicylates and Others. ased on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Allergan PLC (AbbVie), Johnson & Johnson, Merck Group, Amgen, Inc., Eli Lilly and Company, Biogen, Inc., Pfizer, Inc., Novartis AG, Takeda Pharmaceutical Company Limited, and UCB S.A.
Scope of the Study
Market Segments Covered in the Report:
- Crohn's Disease and
- Ulcerative Colitis
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
By Route of Administration
By Drug Class
- TNF inhibitors
- IL inhibitors
- JAK inhibitors
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Allergan PLC (AbbVie)
- Johnson & Johnson
- Merck Group
- Amgen, Inc.
- Eli Lilly and Company
- Biogen, Inc.
- Pfizer, Inc.
- Novartis AG
- Takeda Pharmaceutical Company Limited
- UCB S.A.
Unique Offerings from KBV Research
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free